Earth Science Tech, Inc. (ETST) Sees Uplisting to
Post# of 333
(Total Views: 190)
Posted On: 09/21/2018 6:29:48 PM
Earth Science Tech, Inc. (ETST) Sees Uplisting to OTCQB Venture Market as Key to Goal of being Global Leader in Cannabinoid Market
- Biotech company is focused on becoming a worldwide leader in R&D and sale of hemp-derived, CBD-based nutraceuticals, pharmaceuticals and dietary supplements
- ETST is developing three new CBD formulas in Canada under a provisory patent; it is also clinical testing its Hygee medical device for detecting sexually transmitted diseases in women
- With its Form 10 Registration Statement filing now effective, ETST will begin reporting annual, quarterly and periodic financial statements
Earth Science Tech, Inc. (OTCQB: ETST) anticipates that its uplisting to the OTCQB Venture Market will enable it to reach global recognition and increase liquidity as a leader in the hemp-based CBD space in several fields, such as cannabinoid products. It also develops innovative medical devices designed for multi-national marketing (http://nnw.fm/RZx3Y).
The Florida-based company seeks to raise its recognition level and perform more R&D for the CBD industry. ETST manufactures, markets and distributes its own cannabinoid products, including capsules and oils. It is a leader in the medical cannabis markets, with its products available at retail health food stores and e-liquid smoke shops.
“Historically, up-listing to the OTCQB and being fully reporting has resulted in greater liquidity and awareness,” Nickolas S. Tabraue, president, director and chairman of ETST, stated in a news release (http://nnw.fm/Z9kJ0). “We are committed to the higher level of corporate and financial disclosures required as an OTCQB fully reporting company, demonstrating our commitment to our loyal shareholders.”
In Canada, it is testing three new CBD IP formulations. It is also clinical testing its Hygee MSN-2 medical device for detection of sexually transmitted infections (STIs) in women at Québec’s Clinique Santé Amitié (http://nnw.fm/g4vqP).
It is developing two new products in Brazil in a joint venture with Bionatus Laboratrio Botnico of Brazil and its Canadian division Bionatus Botanical Laboratories, Inc. In the U.S., it is conducting studies with the University of Central Oklahoma on the impact of high grade full spectrum CBD on immune cells and breast cancer (http://nnw.fm/gJqL6).
ETST holds several wholly owned subsidiaries. Cannabis Therapeutics is an emerging biotechnology company. KannaBidioiD manufactures and distributes in the recreational sector. Earth Science Foundation, Inc. is becoming a non-profit and accepts grants and donations to conduct additional studies. Earth Science Pharmaceutical develops medical diagnostic tools and vaccines. It also formed subsidiary Canno Inno Laboratories Inc., a strategic Montreal, Canada-based company that provides ETST with access to government grants.
For more information, visit the company’s website at www.EarthScienceTech.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- Biotech company is focused on becoming a worldwide leader in R&D and sale of hemp-derived, CBD-based nutraceuticals, pharmaceuticals and dietary supplements
- ETST is developing three new CBD formulas in Canada under a provisory patent; it is also clinical testing its Hygee medical device for detecting sexually transmitted diseases in women
- With its Form 10 Registration Statement filing now effective, ETST will begin reporting annual, quarterly and periodic financial statements
Earth Science Tech, Inc. (OTCQB: ETST) anticipates that its uplisting to the OTCQB Venture Market will enable it to reach global recognition and increase liquidity as a leader in the hemp-based CBD space in several fields, such as cannabinoid products. It also develops innovative medical devices designed for multi-national marketing (http://nnw.fm/RZx3Y).
The Florida-based company seeks to raise its recognition level and perform more R&D for the CBD industry. ETST manufactures, markets and distributes its own cannabinoid products, including capsules and oils. It is a leader in the medical cannabis markets, with its products available at retail health food stores and e-liquid smoke shops.
“Historically, up-listing to the OTCQB and being fully reporting has resulted in greater liquidity and awareness,” Nickolas S. Tabraue, president, director and chairman of ETST, stated in a news release (http://nnw.fm/Z9kJ0). “We are committed to the higher level of corporate and financial disclosures required as an OTCQB fully reporting company, demonstrating our commitment to our loyal shareholders.”
In Canada, it is testing three new CBD IP formulations. It is also clinical testing its Hygee MSN-2 medical device for detection of sexually transmitted infections (STIs) in women at Québec’s Clinique Santé Amitié (http://nnw.fm/g4vqP).
It is developing two new products in Brazil in a joint venture with Bionatus Laboratrio Botnico of Brazil and its Canadian division Bionatus Botanical Laboratories, Inc. In the U.S., it is conducting studies with the University of Central Oklahoma on the impact of high grade full spectrum CBD on immune cells and breast cancer (http://nnw.fm/gJqL6).
ETST holds several wholly owned subsidiaries. Cannabis Therapeutics is an emerging biotechnology company. KannaBidioiD manufactures and distributes in the recreational sector. Earth Science Foundation, Inc. is becoming a non-profit and accepts grants and donations to conduct additional studies. Earth Science Pharmaceutical develops medical diagnostic tools and vaccines. It also formed subsidiary Canno Inno Laboratories Inc., a strategic Montreal, Canada-based company that provides ETST with access to government grants.
For more information, visit the company’s website at www.EarthScienceTech.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)